

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	October 15, 2015 June 27, 2023

CHEMET® (succimer)

LENGTH OF AUTHORIZATION: Up to 19 days

REVIEW CRITERIA:

- Patient must be ≥ 12 months of age
- Patient must be diagnosed with lead poisoning by a toxicologist/ specialist with chelating agents (or in consultation with)
- Blood **lead** levels above 45 mcg/dL for children (<18) and above **100** mcg/dL for adults (18 and older) (supporting labs must be submitted with request)
 - Requests below the noted blood lead levels should include clinical rationale supporting treatment

CONTINUATION OF THERAPY:

- Patient met the above criteria; **AND**
- Documentation of rationale for continuation of therapy:
 - Blood **lead** levels above 45 mcg/dL (supporting labs must be submitted with request); **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 100 mg capsules.

REFERENCES:

1. Florida Department of Health. Childhood Lead Poisoning Screening and Case Management Guide. 2023. Available https://www.floridahealth.gov/environmental-health/lead-poisoning/_documents/childhood-leadpoisoning-screening-casemanagement-guide.pdf; pg. 10.